5 completed, 3 recruiting, 3 unknown, 1 active not recruiting. 13 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 5, Recruiting 3, Unknown 3, Active not recruiting 1, Terminated 1 |
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
Follow fasudil: new trials by email Literature Review of fasudil trials Research Report on fasudil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer Fasudil Hydrochloride - Ovarian Cancer | Phase 2 | Recruiting | Zhejiang Provincial People's Hospital | 20 | 2025-04-01 | 2025-03-24 |
| Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapy, Placebo combined with androgen deprivation therapy, radical prostatectomy - Prostate CA | Phase 2 / Phase 3 | Recruiting | baotai Liang | 83 | 2025-02-16 | 2025-11-18 |
| Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD) Fasudil, Placebo - Cognitive Decline, Mild, Alzheimer Disease | Phase 2 | Recruiting | Helse Stavanger HF | 200 | 2024-08-01 | 2026-05-04 |
| Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease Fasudil hydrochloride, Placebo - Idiopathic Parkinson´s Disease | Phase 2 | Completed | Technical University of Munich | 81 | 2023-09-11 | 2026-09-11 |
| Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) Fasudil (WP-0512) - Amyotrophic Lateral Sclerosis | Phase 2 | Active not recruiting | Woolsey Pharmaceuticals | 40 | 2021-12-22 | 2025-04-08 |
| Rho Kinase (ROCK) Inhibitor in Tauopathies - 1 Fasudil - Progressive Supranuclear Palsy, Corticobasal Syndrome | Phase 2 | Unknown | Woolsey Pharmaceuticals | 15 | 2021-01-22 | 2022-06-03 |
| Fasudil fOr redUcing elopemeNt and Spatial Disorientation Oral Fasudil 90 mg/day, Oral Fasudil 180 mg/day, Oral Placebo - Dementia | Phase 2 | Completed | Woolsey Pharmaceuticals | 24 | 2020-12-15 | 2022-07-11 |
| Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS Fasudil, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | University Medical Center Goettingen | 120 | 2019-02-20 | 2023-11-30 |
| Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients injection bevacizumab, injection Combined Bevacizumab and Fasudil - Retinal Vein Occlusion | Phase 2 / Phase 3 | Unknown | Shahid Beheshti University of Medical Sciences | 36 | 2018-01-01 | 2018-01-05 |
| Red Blood Cell ATP Release and Vascular Function in Humans Fasudil Hydrochloride, Saline - Cardiovascular Diseases | Phase 2 | Completed | Colorado State University | 31 | 2017-07-14 | 2020-02-27 |
| A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS) Fasudil - Amyotrophic Lateral Sclerosis | Phase 2 | Unknown | Peking University Third Hospital | 10 | 2013-09-01 | 2013-09-06 |
| Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis Fasudil Hydrochloride, Placebo Oral Tablet - Carotid Stenosis | Phase 2 | Terminated | Brigham and Women's Hospital | 2 | 2008-03-13 | 2017-03-29 |
| The Effect of Fasudil on Vascular Function in Humans fasudil - Atherosclerosis, Hypercholesterolemia | Phase 2 | Completed | Brigham and Women's Hospital | 60 | 2002-06-01 | 2008-09-30 |
Amyotrophic Lateral Sclerosis (3) · Alzheimer Disease (1) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Carotid Stenosis (1) · Cognitive Dysfunction (1) · Corticobasal Degeneration (1) · Dementia (1) · Hypercholesterolemia (1) · Lymphoma, Follicular (1) · Motor Neuron Disease (1) · Neurodegenerative Diseases (1) · Ovarian Neoplasms (1) · Retinal Vein Occlusion (1) · Supranuclear Palsy, Progressive (1)
Woolsey Pharmaceuticals (3) · Brigham and Women's Hospital (2) · Colorado State University (1) · Helse Stavanger HF (1) · Peking University Third Hospital (1) · Shahid Beheshti University of Medical Sciences (1) · Technical University of Munich (1) · University Medical Center Goettingen (1) · Zhejiang Provincial People's Hospital (1) · baotai Liang (1)
United States (6) · China (3) · Australia (2) · Germany (2) · France (1) · Iran (1) · Norway (1) · Switzerland (1)
Anju Nohria, MD (1) · Dongsheng Fan, MD, PhD (1) · Frank Dinenno, PhD (1) · Mark A Creager, MD (1) · Paul Lingor, MD (1) · Peter Ljubenkov, MD (1) · Yang Liu, M.D. (1)
PMID 33533663, PMID 38419648, PMID 39424560, PMID 42235092
2017 (1)